Addex Therapeutics Ltd Stock price

Equities

ADXN

CH0029850754

Biotechnology & Medical Research

Delayed Swiss Exchange 12:30:28 2024-03-28 pm EDT 5-day change 1st Jan Change
0.0956 CHF -1.65% Intraday chart for Addex Therapeutics Ltd +9.89% +107.83%
Sales 2023 * 1.1M 1.22M Sales 2024 * 1.44M 1.6M Capitalization 13.43M 14.88M
Net income 2023 * -11M -12.19M Net income 2024 * -8M -8.86M EV / Sales 2023 * 9.99 x
Net cash position 2023 * 2.45M 2.71M Net cash position 2024 * 362K 402K EV / Sales 2024 * 9.08 x
P/E ratio 2023 *
-0.56 x
P/E ratio 2024 *
-1.06 x
Employees 24
Yield 2023 *
-
Yield 2024 *
-
Free-Float 49.82%
More Fundamentals * Assessed data
Dynamic Chart
1 day-1.65%
1 week+9.89%
Current month+52.72%
1 month+42.69%
3 months+127.62%
6 months+41.00%
Current year+107.83%
More quotes
1 week
0.08
Extreme 0.081
0.10
1 month
0.05
Extreme 0.0512
0.10
Current year
0.05
Extreme 0.045
0.11
1 year
0.04
Extreme 0.0362
0.20
3 years
0.04
Extreme 0.0362
1.73
5 years
0.04
Extreme 0.0362
2.95
10 years
0.04
Extreme 0.0362
5.24
More quotes
Managers TitleAgeSince
Founder 56 01-12-31
Director of Finance/CFO 38 17-05-31
Chairman 75 09-04-15
Members of the board TitleAgeSince
Director/Board Member 54 18-05-31
Founder 56 01-12-31
Chairman 75 09-04-15
More insiders
Date Price Change Volume
24-03-28 0.0956 -1.65% 349,888
24-03-27 0.0972 +2.53% 177,406
24-03-26 0.0948 +3.04% 254,303
24-03-25 0.092 +7.73% 178,210
24-03-22 0.0854 -1.84% 401,304

Delayed Quote Swiss Exchange, March 28, 2024 at 12:30 pm EDT

More quotes
Addex Therapeutics Ltd is a Switzerland-based clinical-stage pharmaceutical company. The Company focuses on development and commercialization of orally available small molecule drugs known as allosteric modulators for neurological disorders. The Company's clinical programs pipeline include dipraglurant (mGlu5 NAM), which is Phase 2a placebo-controlled clinical trial for Parkinson's disease levodopa-induced dyskinesia (PD-LID), and is being prepared to enter registration trials for PD-LID, and ADX71149 (mGlu2 positive allosteric modulator or PAM), which is being developed in collaboration by its partner Janssen Pharmaceuticals, Inc to treat schizophrenia and anxious depression. It also is advancing several preclinical programs, including GABABPAM for pain, overactive bladder and other disorders, mGlu7 NAM for post-traumatic stress disorder, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinson's disease and mGlu3 PAM for neurodegenerative disorders.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
3
Last Close Price
0.0956 CHF
Average target price
0.16 CHF
Spread / Average Target
+67.36%
Consensus
  1. Stock
  2. Equities
  3. Stock Addex Therapeutics Ltd - Swiss Exchange